PL3004875T3 - Predykcyjny biomarker do terapii raka - Google Patents

Predykcyjny biomarker do terapii raka

Info

Publication number
PL3004875T3
PL3004875T3 PL14725114T PL14725114T PL3004875T3 PL 3004875 T3 PL3004875 T3 PL 3004875T3 PL 14725114 T PL14725114 T PL 14725114T PL 14725114 T PL14725114 T PL 14725114T PL 3004875 T3 PL3004875 T3 PL 3004875T3
Authority
PL
Poland
Prior art keywords
cancer therapy
predictive biomarker
biomarker
predictive
cancer
Prior art date
Application number
PL14725114T
Other languages
English (en)
Inventor
Matthias Schroff
Manuel Schmidt
Kerstin KAPP
Burghardt Wittig
Original Assignee
Mologen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologen Ag filed Critical Mologen Ag
Publication of PL3004875T3 publication Critical patent/PL3004875T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G01N33/575
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL14725114T 2013-05-30 2014-05-15 Predykcyjny biomarker do terapii raka PL3004875T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1309657.3A GB2514591A (en) 2013-05-30 2013-05-30 Predictive biomarker for cancer therapy
PCT/EP2014/059995 WO2014191222A1 (en) 2013-05-30 2014-05-15 Predictive biomarker for cancer therapy
EP14725114.4A EP3004875B1 (en) 2013-05-30 2014-05-15 Predictive biomarker for cancer therapy

Publications (1)

Publication Number Publication Date
PL3004875T3 true PL3004875T3 (pl) 2020-11-16

Family

ID=48805478

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14725114T PL3004875T3 (pl) 2013-05-30 2014-05-15 Predykcyjny biomarker do terapii raka

Country Status (17)

Country Link
US (1) US10006032B2 (pl)
EP (1) EP3004875B1 (pl)
JP (1) JP6441320B2 (pl)
KR (1) KR101937442B1 (pl)
CN (2) CN105247365B (pl)
AU (1) AU2014273400B2 (pl)
BR (1) BR112015029852A2 (pl)
CA (1) CA2907980A1 (pl)
DK (1) DK3004875T3 (pl)
ES (1) ES2795929T3 (pl)
GB (1) GB2514591A (pl)
IL (1) IL242551A (pl)
MX (1) MX365512B (pl)
PL (1) PL3004875T3 (pl)
RU (1) RU2672358C2 (pl)
WO (1) WO2014191222A1 (pl)
ZA (1) ZA201506813B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2953216C (en) 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
EP3392345A1 (en) * 2017-04-22 2018-10-24 Mologen AG Biomarker for small cell lung cancer therapy
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
WO2019043192A1 (en) * 2017-08-31 2019-03-07 Mologen Ag TLR-9 AGONISTS FOR TUMOR MICROENVIRONMENT MODULATION

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314682D0 (en) * 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
RU2416797C2 (ru) * 2005-09-08 2011-04-20 Мологен Аг ФУНКЦИОНАЛЬНЫЙ ИММУНОАНАЛИЗ in vitro
US7884197B2 (en) * 2006-12-12 2011-02-08 Idera Pharmaceuticals, Inc. Synthetic agonists of TLR9
AU2008219020B2 (en) * 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
IN2010KN00195A (pl) * 2007-08-01 2015-08-28 Idera Pharmaceuticals Inc
US8853375B2 (en) * 2007-08-15 2014-10-07 Idera Pharmaceuticals, Inc. Toll like receptor modulators
JP5809415B2 (ja) * 2007-11-09 2015-11-10 ペレグリン ファーマシューティカルズ,インコーポレーテッド 抗vegf抗体の組成物および方法
EP2073009A1 (en) * 2007-12-19 2009-06-24 Cell Med Research GMBH Method for T, NK and NKT cells
US20110280930A1 (en) * 2008-05-02 2011-11-17 Facundo Batista Products and methods for stimulating an immune response
WO2009138494A2 (en) * 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators
WO2010136569A1 (en) * 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
US8486908B2 (en) * 2010-11-19 2013-07-16 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
GB201021867D0 (en) * 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
HUE058855T2 (hu) * 2011-08-16 2022-09-28 Morphosys Ag Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
EP2682750A1 (en) * 2012-07-02 2014-01-08 Sotio a.s. In vitro method for the diagnosis and surveillance of cancer

Also Published As

Publication number Publication date
WO2014191222A1 (en) 2014-12-04
EP3004875A1 (en) 2016-04-13
HK1216779A1 (zh) 2016-12-02
MX365512B (es) 2019-06-05
KR20150129860A (ko) 2015-11-20
AU2014273400A1 (en) 2015-10-08
US10006032B2 (en) 2018-06-26
MX2015016305A (es) 2016-03-21
AU2014273400B2 (en) 2017-02-23
RU2015150739A (ru) 2017-07-06
EP3004875B1 (en) 2020-03-04
US20160115479A1 (en) 2016-04-28
KR101937442B1 (ko) 2019-01-11
ES2795929T3 (es) 2020-11-25
CN105247365B (zh) 2019-06-18
CN110201156A (zh) 2019-09-06
CA2907980A1 (en) 2014-12-04
JP6441320B2 (ja) 2018-12-19
BR112015029852A2 (pt) 2017-07-25
GB2514591A (en) 2014-12-03
ZA201506813B (en) 2017-01-25
DK3004875T3 (da) 2020-06-08
IL242551A (en) 2017-07-31
GB201309657D0 (en) 2013-07-17
JP2016526164A (ja) 2016-09-01
RU2672358C2 (ru) 2018-11-14
CN105247365A (zh) 2016-01-13

Similar Documents

Publication Publication Date Title
GB201322725D0 (en) Cancer therapy
PL2931922T3 (pl) Personalizowane biomarkery nowotworu
SG11201506891YA (en) Pre-eclampsia biomarkers
SG11201510210XA (en) Methods for detecting prostate cancer
SG11201509707QA (en) Cancer therapy
GB201322800D0 (en) Prostate cancer biomarkers
EP3052943A4 (en) Biomarkers for cell therapy
GB201321474D0 (en) Novel biomarkers
IL242551A (en) Expectation markers for cancer treatment
SG11201507847UA (en) Cancer therapy
ZA201505937B (en) Caix stratification based cancer treatment
HUE048625T2 (hu) Módszer rák kezelésére
GB201316524D0 (en) Biomarkers
GB201309426D0 (en) Biomarkers
EP2961412A4 (en) CANCER THERAPY
GB201316526D0 (en) Biomarkers
GB201308077D0 (en) Biomarkers
GB201306339D0 (en) Biomarkers for prognosis
EP3015476A4 (en) Tumor biomarker
GB201312638D0 (en) Biomarkers
EP3033617A4 (en) Biomarkers for prostate cancer
GB201316131D0 (en) Biomarkers for disease stratification
GB201304460D0 (en) Biomarker
GB201306394D0 (en) Cancer biomarker
GB201322783D0 (en) Biomarkers